Onkológia 3/2020

CAR T-cells – revolution in cancer immunotherapy?

Therapy with the genetically modified T-cells with the chimeric antigen receptor represents a new approach in the treatment of patients with hematologic malignancies. Two CAR T-cell products have been approved in Europe for the treatment of patients with aggressive Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), however, an extension of indications as well as approval of the new products are expected soon. Treatment with CAR T-cells represents a challenge for health care providers because currently is associated with a complicated process of the drug acquisition and a new spectrum of adverse events which occur infrequently in the daily practice of hematologist or oncologist.

Keywords: CAR, chimeric antigen receptor, immunotherapy, diffuse large B-cell lymphoma, acute lymphoblastic leukemia